<i>miRNA-148b</i> regulates radioresistance in non-small lung cancer cells via regulation of MutL homologue 1

Zhai, Guangsheng; Li, Gaozhong; Xu, Bo; Jia, Tongfu; Zheng, Jianbo; Li, Jianbin

doi:10.1042/bsr20150300

Cited by 15 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, it is considered that the function of miRNAs might be very important in human cancers. Recently years, more and more miRNAs have been recognized involved in the diagnosis, prognosis and progression of different kinds of human cancers, including lung cancers [33][34][35]. MiR-449a, as an example, has been described as the suppressor of NSCLC by Ding and his colleagues in 2014 [36].…”

Section: Discussionmentioning

confidence: 99%

The Prognostic Value of miR-302b in Patients With NSCLC

Zhao

Kong

Wang

2020

Preprint

View full text Add to dashboard Cite

Background: Lung cancer is the most common cancer worldwide. The most frequent type of lung cancer is non-small cell lung cancer (NSCLC). MicroRNAs (miRNAs) have been reported to play important role in human cancers. Studies suggest that the aberrant expression of miRNAs could act as the diagnostic or prognostic biomarker in human cancers, including lung cancer. MicroRNA-302b (miR-302b) has ever been investigated in several human cancers. The aim of this study was to examine the prognostic value of miR-302b in patients with NSCLC.Methods: Quantitative real-time RT-PCR (qRT-PCR) analysis were used to measure the expression level of miR-302b in NSCLC and adjacent noncancerous samples. The relationship of miR-302b with the clinicopathological data of NSCLC was analyzed by Chi-square test. The prognostic value of miR-302b was assessed by using the Kaplan-Meier survival curves and Cox regression analysis.Results: The expression level of miR-302b was downregulated in the NSCLC samples compared with the paired adjacent noncancerous samples (P < 0.05). The decreased miR-302b was found correlated with the differentiation (P = 0.019) and lymph node metastasis (P = 0.019) of NSCLC. The survival curves suggested that patients with lower miR-302b expression had poor overall survival than those with high miR-302b expression. The results of Cox analysis demonstrated that the expression of miR-302b was an independent and effective prognostic factor in NSCLC patients with the P of 0.002 (HR = 2.508, 95% CI = 1.410 - 4.463).Conclusion: In one word, the expression of miR-302b was decreased in NSCLC samples, and the miR-302 expression might act as a prognostic biomarker in NSCLC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The Prognostic Value of miR-302b in Patients With NSCLC

Zhao

Kong

Wang

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Radiotherapy is an essential approach for locally advanced CC. However, around 30% of radiotherapy- Lung cancer miR -198 Inhibiting HGF/c-MET pathway [170] miR-99a Binding to mTOR [171] miR-558 Associating with AATK [172] miR-148b Modulating MutL homologue 1 [173] miR-335 Reducing the expression of PARP-1, downregulating NF-κB [ 174] miR-1246 Inhibiting DR5 [175] miR-21 Upregulating HIF-1α [176] miR-208a Targeting p21 with a corresponding activation of the Akt/mTOR pathway [177] Oral cancer stem cells miR-218 Activating miR-218/Bmi1 axis [178] Hepatocellular carcinoma miR-92b Reducing p57kip2 expression [179] Breast cancer miR-142-3p Attenuating CSCs characteristics and inhibiting β-catenin expression [180] miR-22 Negatively modulating Sirt1 [181] miR-668 Forming miR-668/ IκBα/NF-κB axis [182] Ovarian cancer miR-214 Depressing PETN and consequently activating PI3K/Akt pathway [183] treated patients have been found occurring recurrence or even metastasis, partially resulting from radioresistance. It has been reported that miRNAs participate in either radiation responsiveness or radioresistance.…”

Section: CCmentioning

confidence: 99%

“…Multiple miRNAs have been associated with radiation efficacy in NSCLC, including miR-198, miR-99a, miR-558 and miR-148b [170][171][172][173]. To be specific, overexpression of miR-198 is found to suppress cell proliferation, migration, invasion and promote apoptosis by inhibiting the hepatocyte growth factor (HGF)/c-MET pathway, which overcomes resistance to radiation in NSCLC cells and tissues [170].…”

Section: Lung Cancermentioning

confidence: 99%

“…Similarly, it has been discovered that miR-558 is associated with apoptosis-associated tyrosine kinase (AATK), a radiosensitization-associated gene, and regulates the development of resistance to radiotherapy [172]. The expression of miR-148b is dramatically decreased in both serum and tumor tissues of radioresistant lung cancer patients, and the upregulation of miR-148b can reverse radioresistance by modulating MutL homolog 1 (MLH1), which indicates that miR-148b can serve as a potential biomarker of response to radiation [173]. And in SCLC, it has been reported that elevated miR-335 reduces the expression of poly [ADP-ribose] polymerase 1 (PARP-1) on both mRNA and protein level, correspondingly resulting in the downregulation of NF-κB protein level, thus modulating radiosensitivity of SCLC [174].…”

Section: Lung Cancermentioning

confidence: 99%

See 1 more Smart Citation

Role of non-coding RNAs and RNA modifiers in cancer therapy resistance

et al. 2020

View full text Add to dashboard Cite

As the standard treatments for cancer, chemotherapy and radiotherapy have been widely applied to clinical practice worldwide. However, the resistance to cancer therapies is a major challenge in clinics and scientific research, resulting in tumor recurrence and metastasis. The mechanisms of therapy resistance are complicated and result from multiple factors. Among them, non-coding RNAs (ncRNAs), along with their modifiers, have been investigated to play key roles in regulating tumor development and mediating therapy resistance within various cancers, such as hepatocellular carcinoma, breast cancer, lung cancer, gastric cancer, etc. In this review, we attempt to elucidate the mechanisms underlying ncRNA/modifier-modulated resistance to chemotherapy and radiotherapy, providing some therapeutic potential points for future cancer treatment.

show abstract

“…miRNAs are naturally occurring non-coding small RNA molecules capable of degrading the target mRNA or repressing its translation by targeting mRNA 3′-UTR region [7,8]. Overwhelming evidence shows that miRNA-mediated post-transcriptional regulation plays a critical role in inflammatory response and immune regulation [9,10].…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-322 inhibits inflammatory cytokine expression and promotes cell proliferation in LPS-stimulated murine macrophages by targeting NF-κB1 (p50)

Zhang

Song

et al. 2017

Bioscience Reports

View full text Add to dashboard Cite

Inflammation is the body’s normal self-protection mechanism to eliminate pathogens and resist pathogen invasion. The excessive inflammatory response may lead to inflammatory lesions. The mechanisms accounting for inflammation remain hazy. miRNAs have been proposed to have crucial effects on inflammation. In the present study, we reported that lipopolysaccharide (LPS)-stimulation increased the expression levels of inflammatory cytokines and the cell-cycle progression was suppressed in RAW264.7 cells. Meanwhile, the expression of miR-322 was significantly down-regulated after LPS treatment. Bioinformatics predictions revealed a potential binding site of miR-322 in 3′-UTR of NF-κB1 (p50) and it was further confirmed by luciferase assay. Moreover, both the mRNA and protein levels of NF-κB1 (p50) were down-regulated by miR-322 in RAW264.7 cells. Subsequently, we demonstrated that miR-322 mimics decrease in the expression levels of inflammatory cytokines and cell-cycle repression can be rescued following LPS treatment in RAW264.7 cells. The anti-inflammatory cytokines expression including IL-4 and IL-10 were significantly up-regulated. Furthermore, miR-322 could also promote RAW264.7 cells proliferation. These results demonstrate that miR-322 is a negative regulator of inflammatory response by targeting NF-κB1 (p50).

show abstract

miRNA-148b regulates radioresistance in non-small lung cancer cells via regulation of MutL homologue 1

Abstract: miR-148b regulates radioresistance of lung cancer cells by modulating MLH1 expression level.

Cited by 15 publications

References 31 publications

The Prognostic Value of miR-302b in Patients With NSCLC

The Prognostic Value of miR-302b in Patients With NSCLC

Role of non-coding RNAs and RNA modifiers in cancer therapy resistance

MicroRNA-322 inhibits inflammatory cytokine expression and promotes cell proliferation in LPS-stimulated murine macrophages by targeting NF-κB1 (p50)

Contact Info

Product

Resources

About